Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection

The multidrug-resistant (MDR) human immunodeficiency virus 1 (HIV-1) infection is an unmet medical need. HIV-1 capsid plays an important role at different stages of the HIV-1 replication cycle and is an attractive drug target for developing therapies against MDR HIV-1 infection. Lenacapavir (LEN) is...

Descripción completa

Detalles Bibliográficos
Autores principales: Dzinamarira, Tafadzwa, Almehmadi, Mazen, Alsaiari, Ahad Amer, Allahyani, Mamdouh, Aljuaid, Abdulelah, Alsharif, Abdulaziz, Khan, Abida, Kamal, Mehnaz, Rabaan, Ali A., Alfaraj, Amal H., AlShehail, Bashayer M., Alotaibi, Nouf, AlShehail, Shams M., Imran, Mohd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302933/
https://www.ncbi.nlm.nih.gov/pubmed/37374245
http://dx.doi.org/10.3390/medicina59061041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302933/
https://www.ncbi.nlm.nih.gov/pubmed/37374245
http://dx.doi.org/10.3390/medicina59061041

Ejemplares similares